A Walk-UP LC-MS for the Rapid Analysis of Organic Compounds

用于快速分析有机化合物的直接 LC-MS

基本信息

项目摘要

DESCRIPTION (provided by applicant): . A Liquid Chromatography-Mass Spectrometer (LC-MS) is requested for this Shared Instrumentation Grant application. The instrument consists of a High Performance Liquid Chromatography system coupled to an orthogonal time-of-flight ESI/APCI mass spectrometer, and is to be set up as direct "open-access" instrumentation to researchers (graduate students, postdoctoral fellows, undergraduates, and research technicians). The ability to chemically characterize complex molecule samples lies at the heart of various disciplines, including the chemical sciences in particular. The users of this instrumentation will primarily consist of researchers engaged in the synthesis of novel organic and organometallic molecules that are of importance to biology and human medicine. A versatile LC-MS instrument equipped with an autosampler and "walk-on" access software for student operation will significantly advance several exciting NIH-funded research projects. Each of these efforts depends on the rapid structure elucidation of the molecular products formed in each synthetic process and is therefore directly dependent on the molecular analysis techniques immediately available to the researcher. The availability of open-access LC-MS instrumentation, which allows for immediate access to mass profile data of reactions as they are being performed, will not only increase the rate at which reactions can be performed, but also enhance the accuracy with which each reaction can be scientifically evaluated. This would greatly accelerate the rate at which novel discoveries can be made in the preparation of molecules of biological importance. The associated NIH-funded projects include, but are not limited to, the development of new synthetic methods for the preparation of natural and non-natural molecules of biological and therapeutical interest. These goals involve both target- and diversity-oriented synthesis of novel anti-bacterial, antiviral and antitumor agents, various natural and non-natural products, molecular probes for steroid receptors, radiopharmaceuticals for breast tumor imaging, and small molecule protein mimics for biomedical sensor arrays. PUBLIC HEALTH RELEVANCE: Several NIH-funded investigators in the Department of Chemistry at the University of Illinois seek funding to purchase an instrument for combined liquid chromatography/mass spectrometry. Such an instrument will significantly enhance our ability to analyze organic reactions, ultimately leading to much more rapid progress toward our project goals.
描述(由申请人提供):此共享仪器拨款申请需要一台液质联用(LC-MS)。该仪器由一个与飞行时间正交型ESI/APCI质谱计连接的高效液相色谱系统组成,并将作为研究人员(研究生、博士后、本科生和研究技术人员)的直接“开放式”仪器而设置。对复杂分子样品进行化学表征的能力是各种学科的核心,特别是化学科学。这种仪器的使用者将主要由从事合成对生物学和人类医学具有重要意义的新型有机和有机金属分子的研究人员组成。一种多功能的LC-MS仪器配备了自动取样器和用于学生操作的“随身”访问软件,这将大大促进NIH资助的几个令人兴奋的研究项目。这些努力中的每一项都依赖于在每个合成过程中形成的分子产物的快速结构阐明,因此直接依赖于研究人员立即可用的分子分析技术。开放式LC-MS仪器的可用性允许在进行反应时立即访问大量的反应概况数据,这不仅将提高进行反应的速度,而且还可以提高对每个反应进行科学评估的准确性。这将大大加快在制备具有生物学意义的分子方面取得新发现的速度。NIH资助的相关项目包括但不限于,开发新的合成方法,以制备具有生物和治疗意义的天然和非天然分子。这些目标包括以靶向和多样性为导向合成新型抗菌、抗病毒和抗肿瘤药物、各种天然和非天然产品、类固醇受体分子探针、用于乳腺肿瘤成像的放射性药物以及用于生物医学传感器阵列的小分子蛋白质模拟物。 与公共健康相关:美国国立卫生研究院资助的伊利诺伊大学化学系的几名研究人员寻求资金,购买一种用于液相色谱/质谱分析相结合的仪器。这样的仪器将显著增强我们分析有机反应的能力,最终导致更快地实现我们的项目目标。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Paul Hergenrother其他文献

Paul Hergenrother的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Paul Hergenrother', 18)}}的其他基金

Developing a Suite of Targeted Anticancer Drugs
开发一套靶向抗癌药物
  • 批准号:
    10734624
  • 财政年份:
    2023
  • 资助金额:
    $ 29.93万
  • 项目类别:
FabI Inhibitors as Potent, Gut Microbiome-Sparing Antibiotics
FabI 抑制剂是有效的、保护肠道微生物群的抗生素
  • 批准号:
    10673319
  • 财政年份:
    2023
  • 资助金额:
    $ 29.93万
  • 项目类别:
A Novel Therapeutic Strategy for Ovarian Cancer
卵巢癌的新治疗策略
  • 批准号:
    10446419
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
A Novel Therapeutic Strategy for Ovarian Cancer
卵巢癌的新治疗策略
  • 批准号:
    10588222
  • 财政年份:
    2022
  • 资助金额:
    $ 29.93万
  • 项目类别:
Training Program at the Chemistry Biology Interface
化学生物学接口的培训计划
  • 批准号:
    10202668
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Training Program at the Chemistry Biology Interface
化学生物学接口的培训计划
  • 批准号:
    10623229
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Training Program at the Chemistry Biology Interface
化学生物学接口的培训计划
  • 批准号:
    10441373
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Predictive Guidelines for Penetrance and Discovery of Broad-Spectrum Antibiotics
广谱抗生素外显率和发现的预测指南
  • 批准号:
    10326787
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:
Targeted Therapy for Head and Neck Cancer
头颈癌的靶向治疗
  • 批准号:
    10213008
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:
Targeted Therapy for Head and Neck Cancer
头颈癌的靶向治疗
  • 批准号:
    10413177
  • 财政年份:
    2018
  • 资助金额:
    $ 29.93万
  • 项目类别:

相似海外基金

Development of a new generation of antiviral agents that are effective against drug-resistant viruses and prevent serious illness and sequelae.
开发新一代抗病毒药物,可有效对抗耐药病毒并预防严重疾病和后遗症。
  • 批准号:
    23K18186
  • 财政年份:
    2023
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Grant-in-Aid for Challenging Research (Exploratory)
A versatile structure-based therapeutic platform for development of VHH-based antitoxin and antiviral agents
一个多功能的基于结构的治疗平台,用于开发基于 VHH 的抗毒素和抗病毒药物
  • 批准号:
    10560883
  • 财政年份:
    2023
  • 资助金额:
    $ 29.93万
  • 项目类别:
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10730692
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
Design and synthesis of nucleosides to develop antiviral agents and oligonucleotide therapeutics
设计和合成核苷以开发抗病毒药物和寡核苷酸疗法
  • 批准号:
    21K06459
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Genetically encoded bicyclic peptide libraries for the discoveryof novel antiviral agents
用于发现新型抗病毒药物的基因编码双环肽库
  • 批准号:
    10189880
  • 财政年份:
    2021
  • 资助金额:
    $ 29.93万
  • 项目类别:
Computer-aided identification and synthesis of novel broad-spectrum antiviral agents
新型广谱抗病毒药物的计算机辅助鉴定和合成
  • 批准号:
    2404261
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Studentship
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10222540
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10669717
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
Association between sedentary lifestyle and liver cancer development in hepatitis C patients treated with direct-acting antiviral agents
接受直接抗病毒药物治疗的丙型肝炎患者久坐的生活方式与肝癌发展之间的关系
  • 批准号:
    20K10713
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
    Grant-in-Aid for Scientific Research (C)
Develop broad-spectrum antiviral agents against COVID-19 based on innate immune response to SARS-CoV-2 infection
基于对 SARS-CoV-2 感染的先天免疫反应,开发针对 COVID-19 的广谱抗病毒药物
  • 批准号:
    10174522
  • 财政年份:
    2020
  • 资助金额:
    $ 29.93万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了